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Abstract
We consider two problems of increasing importance in clinical dose finding stud-
ies. First, we assess the similarity of two non-linear regression models for two non-
overlapping subgroups of patients over a restricted covariate space. To this end, we
derive a confidence interval for the maximum difference between the two given models.
If this confidence interval excludes the equivalence margins, similarity of dose response
can be claimed. Second, we address the problem of demonstrating the similarity of two
target doses for two non-overlapping subgroups, using again a confidence interval based
approach. We illustrate the proposed methods with a real case study and investigate
their operating characteristics (coverage probabilities, Type I error rates, power) via
simulation.
Keywords and Phrases: dose finding, equivalence testing, target dose estimation, subgroup
analysis
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1 Introduction
Establishing dose response and selecting optimal dosing regimens is a fundamental step in
the investigation of any new compound, be it a medicinal drug, an herbicide or fertilizer,
a molecular entity, an environmental toxin, or an industrial chemical [1]. This has been
recognized for many years, especially in the drug development area, where patients are
exposed to a medicinal drug once it has been released on the market. An indication of
the importance of properly conducted dose response studies is the early publication of the
tripartite ICH E4 guideline, which gives recommendations on the design and conduct of
studies to assess the relationship between doses, blood levels and clinical response throughout
the clinical development of a new drug [2].
Clinical trials are often analyzed beyond the primary study objectives by assessing efficacy
and safety profiles in clinically relevant subgroups, such as different gender, age classes,
grades of disease severity, etc.; see [3, 4] among many others for clinical examples. A natural
question is then whether the dose response results are consistent across subgroups. To
illustrate the general problem, assume that we are interested in assessing similarity for (a)
two dose response curves or (b) two same target doses, say for male and female patients. For
question (a) we thus want to show that the maximum difference in response between two
(potentially different) non-linear parametric regression models is smaller than a pre-specified
margin. Figure 1a displays an example, where the two dose response curves follow different
Emax models. The maximum response difference over the dose range is indicated by the
arrow. For question (b) we want to show that two same target doses do not differ relevantly.
Figure 1b displays the minimum effective dose (MED) derived from the two previous dose
response models. Here, the MED is defined as the smallest dose which demonstrates a
clinically relevant benefit over placebo, as indicated by the horizontal line in Figure 1b. If we
succeed in demonstrating either (a) or (b), evidence is provided that the difference in response
over the entire dose range or the two target doses differ at most marginally. In practice, such
a result may provide sufficient evidence that the same dose can be administered in both
subgroups (e.g. the same doses for male and female patients).
In this paper we focus on model-based approaches for Phase II dose finding trials. Com-
pared to traditional analysis-of-variance (ANOVA) approaches based on pairwise multiple
comparisons, they have the advantage of enabling the use of more doses in the design,
without requiring a larger number of patients. In an ANOVA-type approach only the in-
formation from the dose levels under investigation is used to declare a dose response signal.
Consequently, the required sample size depends strongly on the number of dose levels under
investigation when a fixed precision is required at each dose level. Modeling techniques allow
one to interpolate information across dose and the total sample size will depend less strongly
on the number of dose levels under investigation. The possibility of using more dose levels
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Figure 1: Assessing similarity for (a) two dose response curves and (b) two same target doses.
will typically result in information-richer trial designs and a better basis for decision making
at the end of Phase II. This has been confirmed by several simulation studies in the liter-
ature, such as the White Paper of the PhRMA working group on “Adaptive Dose-Ranging
Studies” [5]. The main objective of this group was to evaluate different novel and existing
model-based dose ranging methods in a comprehensive simulation study, as compared to
an ANOVA approach. In summary, one can conclude from the PhRMA simulations that
model-based methods outperformed the benchmark ANOVA approach in many cases. In
the meantime, the use of model-based approaches in Phase II dose finding trials has been
supported by several major regulatory agencies [6].
As insinuated by Figure 1, Phase II dose finding trials have multiple, concurrent objectives
[1, 7]. A common objective is to give a complete functional description of the dose response
relationship. An alternative objective is to estimate a target dose for the subsequent confir-
matory Phase III trials. However, demonstrating similarity of target doses or dose response
curves in each of several subgroups has not been addressed in much detail so far in the liter-
ature. One exception is [8], who proposed a non-standard bootstrap approach for question
(a) which addresses the specific form of the interval hypotheses. In particular, data has to be
generated under the null hypothesis using constrained least squares estimates. In this paper
we consider different methods to address both questions (a) and (b). Extending the work
from [9] and using the results from [10], we address problem (a) in Section 2 by deriving a
confidence interval for the maximum difference between the two given non-linear regression
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models over the entire covariate space of interest. If this confidence interval excludes the
equivalence margins, similarity of dose response can be claimed. In Section 3, we consider
asymptotic methods to derive confidence intervals for the difference between two same target
doses to address problem (b). Again, if such a confidence interval excludes a pre-specified
relevance margin, similarity in dose can be claimed. In Section 4 we provide some concluding
remarks. Technical details are left for the Appendix.
2 Assessing similarity of two dose response curves
We consider the non-linear regression models
Yℓ,i,j = mℓ(ϑℓ, dℓ,i) + ǫℓ,i,j , j = 1, . . . , nℓ,i, i = 1, . . . , kℓ, ℓ = 1, 2, dℓ,i ∈ D, (1)
where Yℓ,i,j denotes the jth observed response at the ith dose level dℓ,i under the ℓth dose
response model mℓ. The error terms ǫℓ,i,j are assumed to be independent and identically
distributed with expectation 0 and variance σ2ℓ . Further, nℓ =
∑kℓ
i=1 nℓ,i denotes the sample
size in group ℓ where we assume nℓ,i observations in the ith dose level (i = 1, . . . kℓ, ℓ = 1, 2).
We further assume that for both regression models the different dose levels are attained
on the same (restricted) covariate region D. For the purpose of this paper, we assume
D to be the dose range under investigation, although the results in this section can be
generalized to include other covariates. The functions m1 and m2 in (1) denote the (non-
linear) regression models with fixed but unknown p1- and p2-dimensional parameter vectors
ϑ1 and ϑ2, respectively. Note that both the regression modelsm1 and m2 and the parameters
ϑ1 and ϑ2 may be different. In particular, the design matrices for the two regression models
may be unequal. This implies that we do not assume the same doses to be investigated for
ℓ = 1, 2 and that the sample sizes nℓ can be unequal. We refer to [11] for an overview of
several linear and non-linear regression models commonly employed in clinical studies.
2.1 Methodology
Using results from [10], we derive in the following a confidence interval for the maximum
absolute difference between the two given non-linear regression models m1 and m2 over
the entire covariate space D. We use this confidence interval in order to derive a test
demonstrating similarity of the two dose response curves.
Let U (Y1, Y2, d) denote a 1 − α pointwise upper confidence bound on the difference curve
m2(ϑ2, d) − m1(ϑ1, d), i.e. P {m2(ϑ2, d)−m1(ϑ1, d) ≤ U (Y1, Y2, d)} ≥ 1 − α for all d ∈ D,
where α denotes the pre-specified significance level and Yℓ the vector of observations from
group ℓ = 1, 2. Similarly, let L (Y1, Y2, d) denote a 1−α pointwise lower confidence bound on
m2(ϑ2, d)−m1(ϑ1, d). Using these pointwise confidence bounds we can deduce a confidence
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interval for the maximum absolute difference between the two models maxd∈D |m2(ϑ2, d)−
m1(ϑ1, d)| over the region D, that is
P
{
max
d∈D
|m2(ϑ2, d)−m1(ϑ1, d)| ≤ max
{
max
d∈D
U (Y1, Y2, d) ,−min
d∈D
L (Y1, Y2, d)
}}
≥ 1− α.
(2)
The proof is given in Appendix A. For moderate sample sizes the pointwise confidence bounds
U (Y1, Y2, d) and L (Y1, Y2, d) can be derived from the delta method [12]. Let u1−α denote
the 1− α quantile of the standard normal distribution. Then,
U (Y1, Y2, d) = m2(ϑˆ2, d)−m1(ϑˆ1, d) + u1−αρˆ(d)
and
L (Y1, Y2, d) = m2(ϑˆ2, d)−m1(ϑˆ1, d)− u1−αρˆ(d)
are the desired 1−α asymptotic pointwise upper and lower confidence bounds, respectively,
for m2(ϑ2, d)−m1(ϑ1, d). Here, ϑˆℓ denotes the least squares estimate of ϑℓ and
ρˆ2(d) =
σˆ21
n1
(
∂
∂ϑ1
m1(ϑˆ1, d)
)T
Σˆ−11
(
∂
∂ϑ1
m1(ϑˆ1, d)
)
+
σˆ22
n2
(
∂
∂ϑ2
m2(ϑˆ2, d)
)T
Σˆ−12
(
∂
∂ϑ2
m2(ϑˆ2, d)
)
(3)
is an estimate of the variance of m2(ϑˆ2, d) − m1(ϑˆ1, d). In (3) σˆ2ℓ , is the common variance
estimate in the ℓth group (ℓ = 1, 2) and Σˆℓ =
∑kℓ
i=1
nℓ,i
nℓ
∂
∂ϑℓ
mℓ(xℓ,i,, ϑˆℓ)
(
∂
∂ϑℓ
mℓ(xℓ,i,, ϑˆℓ)
)T
.
Note that the matrix
σˆ2
ℓ
nℓ
Σˆ−1ℓ is a consistent estimator of the covariance matrix of ϑˆℓ (ℓ = 1, 2).
Next we are interested in demonstrating that the maximum absolute difference in response
between the two regression models in (1) over the covariate space D is not larger than a
pre-specified margin δ > 0. Formally, we test the null hypothesis
H : max
d∈D
|m2(ϑ2, d)−m1(ϑ1, d)| ≥ δ (4)
against the alternative hypothesis
K : max
d∈D
|m2(ϑ2, d)−m1(ϑ1, d)| < δ. (5)
Consequently, using the confidence interval (2), equivalence is claimed if
max
{
max
d∈D
U (Y1, Y2, d) ,−min
d∈D
L (Y1, Y2, d)
}
< δ.
Thus, we reject the null hypothesis H at level α and assume similarity of m1 and m2 if
− δ < min
d∈D
L (Y1, Y2, d) and max
d∈D
U (Y1, Y2, d) < δ. (6)
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2.2 Case study
To illustrate the methodology described in Section 2.1, we consider a dose finding trial for
a weight loss drug given to patients suffering from overweight or obesity. This trial aims at
comparing the dose response relationship for two regimens, namely a once-daily (o.d.) and
a twice-daily (b.i.d.) application of the drug. The primary objective in this trial is not to
apply a joint model that includes both regimen, but rather treat both regimen separately
and assess the similarity of dose response. Because this study has not been completed yet, we
simulate data based on the assumptions made at the trial design stage. For confidentiality
reasons, we use blinded dose levels and all chosen dose levels denote the total daily dose.
These limitations do not change the utility of the calculations below.
In this trial, the dose levels for the o.d. and b.i.d. regimens are given by 0.033, 0.1, 1 and
0.067, 0.3, 1, respectively. Patients are thus randomized to receive either placebo or one of
the six active treatments. In total, we assume that 350 patients are allocated equally across
the seven arms, resulting in a sample size of 50 patients per treatment group. The primary
endpoint of the study was the percentage of weight loss after a treatment duration of 20
weeks, with smaller values corresponding to a better treatment effect.
We used the nls function in R [13] to compute the non-linear least squares estimates ϑˆℓ of ϑℓ
and the standard errors necessary for calculating U (Y1, Y2, d) and L (Y1, Y2, d) from Section
2.1. The R code for this example and all other calculations in this paper is available from
the authors upon request.
For this example, we fitted two Emax models: m1(ϑ1, d) = ϑ1,1 + ϑ1,2
d
ϑ1,3+d
for the o.d.
regimen and m2(ϑ2, d) = ϑ2,1 + ϑ2,2
d
ϑ2,3+d
for the b.i.d. regimen, where ϑ1 = (ϑ1,1, ϑ1,2, ϑ1,3)
and ϑ2 = (ϑ2,1, ϑ2,2, ϑ2,3). For the data set at hand, ϑˆ1 = (0.55,−5.66, 6.55) and ϑˆ2 =
(−0.54,−6.42, 41.99). Figure 2a displays the fitted dose response models m1(ϑˆ1, d) and
m2(ϑˆ2, d), d ∈ [0, 1], together with the individual observations, where the vertical axis is
truncated to [−7, 1] for better readability. Figure 2b displays the difference m2(ϑˆ2, d) −
m1(ϑˆ1, d) together with the associated 90% pointwise confidence intervals for each dose
d ∈ [0, 1]. The maximum upper confidence bound for α = 0.1 is maxd∈D U (Y1, Y2, d) = 2.099
at dose d = 0.1 and the minimum lower confidence bound is mind∈D L (Y1, Y2, d) = −2.748
at the minimum dose d = 0. That is, the maximum difference in response between the two
regimens over the dose range D = [0, 1] lies between −2.748 and 2.099. Therefore, similarity
of the dose response curves can be claimed at level α = 0.1 as long as δ is larger than 2.748,
according to (6).
2.3 Simulations
We conducted a simulation study to investigate the operating characteristics of the method
described in Section 2.1. We investigated coverage probabilities of the confidence intervals
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Figure 2: Plots for the weight loss case study. (a) The fitted Emax model m1 (m2) for the
o.d. (b.i.d.) regimen is given by the solid (dashed) line with observations marked by “x”
(“o”). (b) Mean difference curve with associated pointwise 90% confidence bounds. Bold
dots denote the maximum upper and minimum lower confidence bound over D = [0, 1].
as well as Type I error rates and power of the test (6) for different scenarios. To simplify
the simulations, we assumed balanced designs and that dose is the only covariate. For all
simulations below, we generated data as follows:
Step 1: Specify the models m1, m2, their parameters ϑ1, ϑ2, a common variance σ
2 and the
actual dose levels dℓ,i.
Step 2: Generate nℓ,i values mℓ(ϑℓ, dℓ,i) at each dose dℓ,i.
Step 3: Generate normally distributed residual errors ǫℓ,i,j ∼ N(0, σ2) and use the final re-
sponse data
Yℓ,i,j = mℓ(ϑℓ, dℓ,i) + ǫℓ,i,j, j = 1, . . . , nℓ,i, i = 1, . . . kℓ, ℓ = 1, 2. (7)
This procedure is repeated using 10, 000 simulation runs. Because of the large number of
scenarios, only a subset of the possible results is included below to illustrate the key findings.
The complete simulations results are available in [14].
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2.3.1 Coverage probabilities
In the following we report the coverage probabilities of the confidence intervals for the
maximum absolute difference derived in (2) under two different scenarios.
Scenario 1 We start with the comparison of a linear and a quadratic model. More specif-
ically, we chose the linear model m1(d) = d and the quadratic model m2(d) = 3δ1 + (1 −
4δ1)d + δ1d
2, d ∈ [1, 3]; see Figure 3a for δ1 = 1. We assumed identical dose levels dℓ,i = i,
i = 1, 2, 3 for both regression models ℓ = 1, 2. Consequently, the two curves coincide at
the two boundary doses d = 1, 3, and the maximum difference δ1 occurs at dose d = 2.
For each configuration of σ2 = 1, 2, 3 and δ1 = 1, 2, 3 we used (7) to simulate nℓ,i = 10(50)
observations at each dose level dℓ,i, resulting in nℓ = 30(150), ℓ = 1, 2.
(a) Scenario 1 (b) Scenario 2
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Figure 3: Graphical illustration of the two scenarios used for the simulations. Open dots
in the left panel indicate the actual dose levels. In the right panel they indicate the doses
where the maximum distance to the reference curve m1 (dashed line) is observed.
The left side of Table 1 displays the coverage probabilities for α = 0.05, 0.1. We observe
that the nominal level of 1 − α is reached in all cases under consideration, which confirms
(2). The confidence intervals are more accurate for larger sample sizes and smaller variances,
because we used the asymptotic quantiles from the normal distribution. If, instead, we select
the quantiles from the t distribution, the simulated coverage probabilities are closer to the
nominal 1 − α level (results not shown here). Note that the confidence bounds perform
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better for larger values of δ1. This effect can be explained by a careful look at the proof
given in Appendix A and the particular example under consideration. First note that the
maximum absolute difference δ1 between the two curves is attained at a single point, say
d0; see Figure 3a. If this difference is large then either maxd∈D U (Y1, Y2, d) = U (Y1, Y2, d0)
or −mind∈D L (Y1, Y2, d) = L (Y1, Y2, d0) with high probability and consequently there is
equality either in (16) or (17) in Appendix A. The same effect appears for increasing sample
sizes and smaller values of δ1 as in this case the parameter estimates and approximation of
the coverage probability of the confidence interval are more precise.
Coverage probabilities Type I error rates
α = 0.05 α = 0.1 α = 0.05 α = 0.1
δ1 σ
2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
1 1 0.987 0.950 0.950 0.953 0.915 0.906 0.012 0.050 0.050 0.046 0.085 0.095
1 2 0.999 0.973 0.956 0.991 0.929 0.906 0.001 0.027 0.042 0.009 0.071 0.088
1 3 1.000 0.992 0.971 0.999 0.965 0.923 0.000 0.008 0.031 0.001 0.035 0.077
2 1 0.949 0.942 0.952 0.901 0.909 0.907 0.047 0.058 0.049 0.096 0.091 0.105
2 2 0.960 0.959 0.951 0.913 0.911 0.901 0.039 0.051 0.048 0.079 0.089 0.095
2 3 0.977 0.946 0.950 0.936 0.902 0.902 0.025 0.054 0.047 0.065 0.099 0.097
3 1 0.951 0.945 0.954 0.906 0.904 0.908 0.053 0.055 0.048 0.102 0.096 0.100
3 2 0.952 0.941 0.954 0.905 0.895 0.907 0.048 0.059 0.047 0.094 0.105 0.099
3 3 0.949 0.946 0.952 0.900 0.902 0.903 0.052 0.054 0.049 0.098 0.098 0.099
Table 1: Simulated coverage probabilities and Type I error rates for different configurations
of δ1, σ
2, α, and nℓ under Scenario 1.
Scenario 2 We now consider the comparison of two different Emax models, where the
maximum distances with respect to the same reference model are 0.25, 0.5, 1, 1.5 and 2.
More specifically, we compared the reference Emax model m1(d) = 1 +
9.70d
6.70+d
with
m12(d) = 1+
6.88d
3.60 + d
, m22(d) = 1+
5.66d
2.25 + d
, m32(d) = 1+
4.52d
1 + d
, m42(d) = 1+
4.05d
0.48 + d
, m52(d) = 1+
3.82d
0.22 + d
,
(8)
where the dose range is given by D = [0, 4]. Note that the placebo response at d = 0 is 1 and
the response at the highest dose d = 4 is 4.62 for all five models; see Figure 3b. The difference
curve is given by mh2(ϑ
h
2 , d)−m1(ϑ1, d) for h = 1, 2, 3, 4, 5. Note that the dose which produces
the maximum difference is different for each h. More precisely, these doses are given by
1.4, 1.28, 1.04, 0.82 and 0.61 for h = 1, . . . , 5; see again Figure 3b. The maximum absolute
distance attained at each of these doses is denoted by δ∞ = maxd∈D
∣∣mh2(ϑh2 , d)−m1(ϑ1, d)∣∣.
We assumed identical dose levels dℓ,i = i − 1, i = 1, 2, 3, 4, 5 for both regression models
ℓ = 1, 2. For each configuration of σ2 = 1, 2, 3 and δ∞ = 0.25, 0.5, 1, 1.5, 2, we used (7) to
simulate nℓ,i = 30 observations at each dose level dℓ,i, resulting in nℓ = 150, ℓ = 1, 2.
The left side of Table 2 displays the coverage probabilities for α = 0.05, 0.1. As already
seen under Scenario 1, the confidence intervals are more accurate for smaller variances (and
larger sample sizes, results not shown here) and for increasing values of δ∞. As before,
asymptotically the coverage probability is at least 1−α under all configurations investigated
here.
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Coverage probabilities Type I error rates
α = 0.05 α = 0.1 α = 0.05 α = 0.1
(m1, m2) δ∞ σ
2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
(m1, m
1
2
) 0.25 1 1.000 1.000 1.000 1.000 1.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000
2 1.000 1.000 1.000 1.000 1.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000
3 1.000 1.000 1.000 1.000 1.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000
(m1, m
2
2
) 0.5 1 1.000 1.000 0.994 1.000 0.990 0.960 0.000 0.000 0.006 0.000 0.001 0.040
2 1.000 1.000 1.000 1.000 1.000 0.993 0.000 0.000 0.000 0.000 0.000 0.007
3 1.000 1.000 1.000 1.000 1.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000
(m1, m
3
2
) 1 1 0.995 0.957 0.954 0.980 0.902 0.893 0.005 0.042 0.036 0.002 0.097 0.107
2 1.000 0.981 0.963 1.000 0.936 0.903 0.000 0.019 0.047 0.000 0.064 0.097
3 1.000 0.996 0.983 1.000 0.968 0.942 0.000 0.004 0.015 0.000 0.031 0.058
(m1, m
4
2
) 1.5 1 0.971 0.939 0.952 0.921 0.868 0.899 0.029 0.061 0.048 0.078 0.131 0.101
2 0.996 0.961 0.962 0.966 0.910 0.913 0.004 0.038 0.038 0.033 0.090 0.087
3 1.000 0.965 0.949 0.987 0.907 0.897 0.000 0.035 0.051 0.012 0.092 0.103
(m1, m
5
2
) 2 1 0.940 0.929 0.945 0.897 0.867 0.902 0.060 0.071 0.055 0.102 0.132 0.098
2 0.958 0.940 0.942 0.903 0.878 0.889 0.041 0.060 0.068 0.096 0.122 0.118
3 0.991 0.940 0.941 0.957 0.874 0.896 0.008 0.060 0.065 0.042 0.126 0.116
Table 2: Simulated coverage probabilities and Type I error rates for different model choices
and configurations of σ2 and α under Scenario 2, for nℓ = 30, 90, 150, ℓ = 1, 2.
2.3.2 Type I error rates
For the Type I error rate simulations we investigated the two scenarios from Figure 3 for
each configuration of α = 0.05, 0.1 and σ2 = 1, 2, 3. Further, we set δ = δ∞ in (4). For
a fixed configuration, we generated data according to (7), fit both models, performed the
hypothesis test (6) and counted the proportion of rejecting the null hypothesis H . Note that
due to the choice of δ both Scenarios 1 and 2 belong to the null hypothesis H defined in (4).
Thus, rejecting H would be a Type I error, i.e. we would erroneously claim similarity of the
two dose response curves.
The right side of Table 1 displays the simulated Type I error rates under Scenario 1. We
observe that the simulated Type I error rate is bounded by the nominal significance level
α for all configurations investigated here, indicating that the hypothesis test (6) is indeed
a level-α test, even under total sample sizes as small as 30. Note also that the significance
level is actually well exhausted under many configurations. For small sample sizes and
small values of δ the test becomes conservative, matching the observed performance of the
confidence bounds shown in the left side of Table 1. Again, this conservatism disappears for
large sample sizes.
The right side of Table 2 displays the simulated Type I error rates under Scenario 2. As
before, the simulated Type I error rate is bounded by the nominal significance level α under
all configurations. However, we observe that the test is very conservative for small values of
δ∞, as already expected from the previously reported results on the coverage probabilities.
2.3.3 Power
We now consider testing the null hypothesis H in (4) for δ = 1, where in fact the maximum
difference is smaller than 1. We start with the comparison of the models from Scenario 1 for
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different values of δ1 under the alternative; see Figure 4. The dose levels remain the same
as under Scenario 1. For each configuration of σ2 = 1, 2, 3 and δ1 = 0, 0.25, 0.5, 0.75, 0.9, we
used (7) to simulate n = 10(30, 50) observations under m1 and m2 at each dose level dℓ,i,
resulting in nℓ = 30(90, 150), ℓ = 1, 2. Table 3 summarizes the results for α = 0.05, 0.1. The
power increases with decreasing values of δ1. For large values of σ
2 the power remains small,
even for δ1 = 0. In these cases we need larger sample sizes nℓ in order to achieve reliable
results, as otherwise, due to the large variances, the confidence intervals in (2) become too
wide and hence the test very conservative.
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Figure 4: Graphical illustration of Scenario 1 used for the power simulations. Open dots
indicate the actual dose levels.
Regarding Scenario 2, we tested the null hypothesis H in (4) using δ = 1 and generating
data under the models m1, m
1
2 and m
2
2 defined in (8). Hence we simulated the performance
of the test under the alternative K in (5) for different choices of σ and α. For the sake of
brevity we restrict ourselves again to a fixed total sample size of nℓ = 150, ℓ = 1, 2. Table 4
displays the simulated power. We observe that the test achieves high power, even for larger
variances. However, the power decreases for an increasing true maximum distance between
the models and for increasing variances.
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α = 0.05 α = 0.1
δ1 σ
2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
0.00 1 0.211 0.966 0.999 0.426 0.988 0.999
0.25 1 0.170 0.939 0.997 0.377 0.974 0.999
0.50 1 0.102 0.731 0.917 0.268 0.843 0.958
0.75 1 0.046 0.306 0.444 0.143 0.433 0.583
0.90 1 0.023 0.111 0.144 0.074 0.195 0.245
0.00 2 0.002 0.544 0.911 0.046 0.749 0.967
0.25 2 0.001 0.479 0.867 0.045 0.692 0.941
0.50 2 0.001 0.302 0.628 0.030 0.500 0.770
0.75 2 0.000 0.119 0.247 0.012 0.245 0.391
0.90 2 0.000 0.050 0.098 0.011 0.128 0.181
0.00 3 0.000 0.196 0.651 0.007 0.434 0.822
0.25 3 0.000 0.162 0.576 0.005 0.382 0.758
0.50 3 0.000 0.098 0.365 0.004 0.263 0.558
0.75 3 0.000 0.040 0.142 0.002 0.128 0.276
0.90 3 0.000 0.021 0.050 0.001 0.072 0.126
Table 3: Simulated power for δ = 1 and different configurations of δ1, σ
2, α, and nℓ in
Scenario 1.
α = 0.05 α = 0.1
(m1, m2) δ∞ σ
2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
(m1, m1) 0 1 0.038 0.837 0.986 0.206 0.930 0.996
(m1, m
1
2) 0.25 1 0.036 0.770 0.980 0.175 0.876 0.992
(m1, m
2
2) 0.5 1 0.026 0.610 0.871 0.121 0.763 0.938
(m1, m1) 0 2 0.001 0.257 0.719 0.003 0.517 0.873
(m1, m
1
2) 0.25 2 0.000 0.220 0.657 0.005 0.493 0.833
(m1, m
2
2) 0.5 2 0.000 0.083 0.442 0.001 0.257 0.655
(m1, m1) 0 3 0.000 0.023 0.350 0.000 0.180 0.622
(m1, m
1
2) 0.25 3 0.000 0.023 0.286 0.000 0.153 0.553
(m1, m
2
2) 0.5 3 0.000 0.010 0.183 0.000 0.117 0.400
Table 4: Simulated power for different model choices and configurations of σ2 and α under
Scenario 2, for δ = 1 and nℓ = 30, 90, 150, l = 1, 2.
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2.4 Placebo-adjusted modeling
So far we assessed the similarity of two dose response models in terms of the maximum
difference over the dose range under investigation. Sometimes one might be interested in
adjusting for the placebo response, that is, the treatment effect relative to the placebo
response, before comparing two dose response curves. In this case one has to modify the
results from Section 2.1 as follows. Different to model (1), we consider the placebo-adjusted
responses
Yℓ,i,j = mℓ (ϑℓ, dℓ,i)−mℓ (ϑℓ, 0) + ǫℓ,i,j, j = 1, . . . , nℓ,i, i = 1, . . . kℓ, ℓ = 1, 2, dℓ,i ∈ D.
The confidence interval for the maximum absolute difference between the placebo-adjusted
curves is then given by
P
{
max
d∈D
|(m2(ϑ2, d)−m2(ϑ2, 0)) − (m1(ϑ1, d) −m1(ϑ1, 0))| ≤ max
{
max
d∈D
U ′ (Y1, Y2, d) ,−min
d∈D
L′ (Y1, Y2, d)
}}
≥ 1− α,
where U ′ (Y1, Y2, d) and L
′ (Y1, Y2, d) denote the pointwise confidence bounds for the placebo-
adjusted differences derived by the delta method. For example,
U ′ (Y1, Y2, d) = (m2(ϑˆ2, d)−m2(ϑˆ2, 0))− (m1(ϑˆ1, d)−m1(ϑˆ1, 0)) + u1−αρˆ
′(d),
where ρˆ′(d) is calculated for the difference of two placebo-adjusted dose response curves.
Proceeding, the null hypothesis of interest becomes
H ′ : max
d∈D
|(m2(ϑ2, d)−m2(ϑ2, 0))− (m1(ϑ1, d)−m1(ϑ1, 0))| ≥ δ
and following (6) we reject H ′ if
−δ < min
d∈D
L′ (Y1, Y2, d) and max
d∈D
U ′ (Y1, Y2, d) < δ. (9)
To illustrate this methodology, we revisit the weight loss case study from Section 2.2. The
individual model fits remain the same, i.e. m1(ϑ1, d) = 0.55−5.66
d
6.55+d
for the o.d. regimen
and m2(ϑ2, d) = −0.54 − 6.42
d
41.99+d
for the b.i.d. regimen. Figure 5a displays the placebo-
adjusted model fits m1(ϑˆ1, d)−m1(ϑˆ1, 0) and m2(ϑˆ2, d)−m2(ϑˆ2, 0), d ∈ [0, 1], together with
the individual observations, where only the range [−7, 1] is displayed on the vertical axis for
better readability. Figure 5b displays the difference (m2(ϑˆ2, d) −m2(ϑˆ2, 0)) − (m1(ϑˆ1, d) −
m1(ϑˆ1, 0)) together with the associated 90% pointwise confidence intervals for each dose
d ∈ [0, 1]. In this example, the estimated placebo effects from the original fits were slightly
different to 0. Thus, the placebo-adjusted difference curve and its confidence bounds differ
slightly from the previous results in Section 2.2; see Figure 2. The maximum upper confidence
bound for α = 0.1 is maxd∈D U
′ (Y1, Y2, d) = 3.186, again observed at dose d = 0.1, and the
minimum lower confidence bound is mind∈D L
′ (Y1, Y2, d) = −1.661 at dose d = 0. That
is, the maximum placebo-adjusted difference between the two regimens over the dose range
D = [0, 1] lies between −1.661 and 3.186. Therefore, similarity of the placebo-adjusted dose
response curves can be claimed according to (9) as long as δ is larger than 3.186.
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Figure 5: Placebo-adjusted plots for the weight loss case study. (a) The placebo-adjusted
Emax model fit m1 (m2) for the o.d. (b.i.d.) regimen is given by the solid (dashed) line with
observations marked by “x” (“o”). (b) Mean difference curve with associated pointwise 90%
confidence bounds. Bold dots denote the maximum upper and minimum lower confidence
bound over D = [0, 1].
3 Assessing the similarity of two target doses
This section focuses on assessing the similarity of two target doses. We consider the difference
between the minimum effective doses (MEDs) of two dose response curves from two non-
overlapping subgroups. We derive confidence intervals and statistical tests to decide at a
given level α whether the absolute difference of two MEDs is smaller than a prespecified
margin η. Furthermore, we illustrate the proposed methodology by revisiting the case study
from 2.2 and investigate its operating characteristics.
3.1 Methodology
Following [1], the MED is defined as the smallest dose that produces a clinically relevant
response ∆ on top of the placebo effect (i.e. at dose d = 0). That is,
MEDℓ = MEDℓ(ϑℓ) = inf
d∈D
{mℓ(ϑℓ, 0) < mℓ(ϑℓ, d)−∆} , ℓ = 1, 2. (10)
14
From now on we assume strict monotonicity of the dose response curves mℓ such that (10)
becomes
MEDℓ =MEDℓ(ϑℓ) = m
−1
ℓ (ϑℓ, mℓ(ϑℓ, 0) + ∆), ℓ = 1, 2,
where the inverse is calculated with respect to d for fixed model parameters ϑ1 and ϑ2.
Estimates for the MED are then given by
M̂EDℓ = m
−1
ℓ (ϑˆℓ, mℓ(ϑˆℓ, 0) + ∆), ℓ = 1, 2,
where ϑˆ1 and ϑˆ2 are the non-linear least squares estimators for the true parameters. Due to
the asymptotic normality of the estimates ϑˆ1 and ϑˆ2, the estimated difference of the MEDs
is approximately normal distributed [15]. To be more precise, the delta method [12] gives
M̂ED1 − M̂ED2 − (MED1 −MED2) ≈ N (0, τ
2), (11)
for
τ 2 =
(
∂
∂ϑ1
m−11 (ϑ1,∆1)
)T
σ21
n1
Σ−11
∂
∂ϑ1
m−11 (ϑ1,∆1) +
(
∂
∂ϑ2
m−12 (ϑ2,∆2)
)T
σ22
n2
Σ−12
∂
∂ϑ2
m−12 (ϑ2,∆2)
and ∆ℓ = mℓ(ϑℓ, 0) + ∆, ℓ = 1, 2. The variance τ
2 can be estimated by replacing ϑℓ and
Σℓ by their estimates ϑˆℓ and Σˆℓ, ℓ = 1, 2; see Section 2.1. The corresponding estimator is
denoted by τˆ 2. It then follows from (11) that
P
{
MED1 −MED2 ∈
[
M̂ED1 − M̂ED2 − u1−α/2τˆ , M̂ED1 − M̂ED2 + u1−α/2τˆ
]}
n1,n2→∞
−→ 1−α,
(12)
and an asymptotic (1− α)-confidence interval for the difference of the MEDs is given by
[
M̂ED1 − M̂ED2 − u1−α/2τˆ , M̂ED1 − M̂ED2 + u1−α/2τˆ
]
.
In order to derive a test for similarity of two target doses we consider the problem of testing
H ′′ : |MED1 −MED2| ≥ η against K
′′ : |MED1 −MED2| < η. (13)
In Appendix B we show that rejecting H ′′ if
|M̂ED1 − M̂ED2| < c, (14)
gives an asymptotic (uniformly most powerful) level α test, where c is the unique solution
of the equation
α = Φ
(
c− η
τˆ
)
− Φ
(
−c− η
τˆ
)
. (15)
Note that (15) can easily be solved by using Newton’s algorithm [16].
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3.2 Case study revisited
To illustrate the methodology in the previous subsection, we revisit the weight loss case study
from Section 2.2. Recall the individual model fits m1(ϑˆ1, d) = 0.55 − 5.66
d
6.55+d
for the o.d.
regimen and m2(ϑˆ2, d) = −0.54 − 6.42
d
41.99+d
for the b.i.d. regimen. We chose a clinically
relevant difference of ∆ = −3. That is, a weight loss of 3% compared to the placebo response
is assumed to be a clinically relevant effect on top of the placebo response at dose d = 0.
Therefore, M̂ED1 = m
−1
1 (ϑˆ1, 0.55 − 3) = 0.049, M̂ED2 = m
−1
2 (ϑˆ2,−0.54 − 3) = 0.246 and
M̂ED1− M̂ED2 = −0.196. Figure 6(a) displays the model fits mℓ(ϑˆℓ, d), together with the
estimates M̂EDℓ, ℓ = 1, 2.
The 1 − α confidence interval for the true difference MED1 − MED2 is then given by[
−0.197− u1−α/20.199,−0.197 + u1−α/20.199
]
. For example,MED1−MED2 ∈ [−0.589, 0.195]
for α = 0.05 and MED1 −MED2 ∈ [−0.526, 0.132] for α = 0.1. Applying the test in (14)
for α = 0.05 allows us to claim similarity of the two MEDs whenever η > 0.526 because of
c > 0.197 = |M̂ED1 − M̂ED2| in (15). Figure 6(b) displays the value of c as a function of
η. For α = 0.1 we obtain by similar calculations that η has to be larger than 0.453 in order
to claim similarity.
3.3 Simulations
We now report the results of a simulation study to investigate the operating characteristics
of the method described in Section 3.1. Adapting the data generation algorithm from Sec-
tion 2.3, we investigated the coverage probabilities of the confidence intervals in (12) as well
as the Type I error rates and power of the test (14) for different scenarios. All results were
obtained using 10, 000 simulation runs. Again we refer to [14] for the complete simulations
results.
3.3.1 Coverage probabilities
Scenario 3 We start with the comparison of two shifted Emax models m1(d, ϑ1) = δ1 +
5d/(1 + d) and m2(d, ϑ2) = 5d/(1 + d) over D = [0, 4], with identical dose levels dℓ,i =
i − 1, i = 1, . . . , 5 for both regression models ℓ = 1, 2; see Figure 7a. Because the models
are shifted by the constant δ1, the true difference MED1 −MED2 = 0 regardless of the
value for ∆. For each configuration of σ2 = 1, 2 and δ1 = 1, 2, 3 we used (7) to simulate
nℓ,i = 6(30) observations at each dose level dℓ,i, resulting in nℓ = 30(150), ℓ = 1, 2.
The left side of Table 5 displays the coverage probabilities for α = 0.05, 0.1. We observe that
the coverage probability is at least 1−α under all configurations. The confidence intervals are
more accurate for larger sample sizes and smaller variances, which confirms the asymptotic
result from (12). Furthermore, the simulated differences between the MED estimates are
very close to the true difference under all configurations (results not shown here).
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Figure 6: Plots for the revisited weight loss case study. (a) The fitted Emax model m1 (m2)
for the o.d. (b.i.d.) regimen is given by the solid (dashed) line, together with the estimated
MEDs for ∆ = −3. (b) Plot of the unique solution c of equation (15) as a function of η.
The dashed lines indicate the absolute difference of the MED estimates and the minimum
choice of η in order to claim similarity for α = 0.05.
Coverage probabilities Type I error rates
α = 0.05 α = 0.1 α = 0.05 α = 0.1
δ1 σ
2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
1 1 0.979 0.948 0.959 0.941 0.926 0.907 0.050 0.048 0.050 0.103 0.110 0.103
2 1 0.982 0.962 0.958 0.945 0.917 0.909 0.053 0.051 0.048 0.105 0.102 0.105
3 1 0.980 0.972 0.961 0.946 0.922 0.908 0.053 0.052 0.052 0.099 0.100 0.105
1 2 0.996 0.968 0.967 0.977 0.948 0.917 0.049 0.049 0.051 0.104 0.104 0.101
2 2 0.996 0.969 0.968 0.978 0.959 0.922 0.052 0.050 0.049 0.103 0.100 0.101
3 2 0.995 0.977 0.966 0.976 0.923 0.916 0.045 0.048 0.049 0.100 0.098 0.099
1 3 0.999 0.978 0.977 0.979 0.941 0.927 0.050 0.062 0.051 0.104 0.110 0.101
2 3 0.998 0.971 0.969 0.979 0.952 0.925 0.058 0.058 0.049 0.103 0.102 0.111
3 3 0.995 0.981 0.967 0.978 0.923 0.918 0.044 0.049 0.049 0.100 0.092 0.088
Table 5: Simulated coverage probabilities and Type I error rates for different configurations
of δ1, σ
2, α, and nℓ under Scenario 3.
Scenario 4 We now consider the comparison of the Emax model m1(d, ϑ1) = 1+4d/(2+d)
with the linear model m2(d, ϑ2) = 1 + 0.8d for the same set of doses as in Scenario 3. Note
that the responses at doses d = 0 and d = 3 are the same in both models; see Figure 7b.
For each configuration of σ2 = 1, 2, 3 and ∆ = 0.8, 1.6, 2.4, we used again (7) to simulate
nℓ,i = 6(30) observations at each dose level dℓ,i, resulting in nℓ = 30(150), ℓ = 1, 2.
The left side of Table 6 displays the coverage probabilities for α = 0.05, 0.1. As before,
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Figure 7: Graphical illustration of Scenarios 3 and 4 used for the simulations. (a) displays
the shifted Emax models with δ1 = 2. (b) displays the curves for Scenario 4, together with
the MEDs corresponding to ∆ = 1.6.
asymptotically the coverage probability is at least 1−α under all configurations investigated
here, except for small sample sizes and ∆ = 2.4 (in which case the MEDs coincide). This
is a direct consequence of the definition of the MED. Inverting an Emax model m(ϑ, d) =
y = ϑ1 + ϑ2d/(ϑ3 + d) gives m
−1
1 (ϑ, y) = ϑ3(y − ϑ1)/(ϑ1 + ϑ3 − y). Therefore higher values
of ∆ result in being closer to the pole of m−1, which is at ϑ1 +ϑ2 = 5 in this case. However,
further simulations show that the results get better for larger sample sizes and the coverage
probabilities converge quickly to their nominal values. Finally, the simulated differences
between the MED estimates are very close to the true difference under all configurations,
except in the case where the MEDs coincide (i.e. ∆ = 2.4; results not shown here).
3.3.2 Type I error rates
For the Type I error rate simulations we investigated the two scenarios from Figure 7.
We start with Scenario 3. Because |MED1 − MED2| = 0 for all values of ∆, we chose
η = 0. For a fixed configuration of parameters, we generated data according to (7), fit both
models, performed the hypothesis test (14) and counted the proportion of rejecting the null
hypothesis H ′′. The right side of Table 5 displays the simulated Type I error rates under
Scenario 3. We observe that the simulated Type I error rate is well exhausted at the nominal
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Coverage probabilities Type I error rates
α = 0.05 α = 0.1 α = 0.05 α = 0.1
∆ σ2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
0.8 1 0.964 0.960 0.965 0.929 0.914 0.908 0.036 0.025 0.025 0.077 0.059 0.068
1.6 1 0.953 0.951 0.946 0.922 0.913 0.903 0.051 0.048 0.040 0.098 0.088 0.087
2.4 1 0.920 0.932 0.949 0.877 0.900 0.916 0.069 0.055 0.057 0.137 0.121 0.116
0.8 2 0.989 0.953 0.968 0.960 0.924 0.928 0.050 0.038 0.026 0.101 0.063 0.061
1.6 2 0.967 0.964 0.956 0.936 0.907 0.913 0.053 0.046 0.045 0.111 0.087 0.088
2.4 2 0.918 0.919 0.932 0.870 0.888 0.901 0.069 0.054 0.060 0.143 0.125 0.124
0.8 3 0.969 0.959 0.969 0.925 0.921 0.945 0.055 0.039 0.029 0.100 0.092 0.074
1.6 3 0.989 0.971 0.964 0.913 0.902 0.919 0.044 0.046 0.043 0.113 0.096 0.098
2.4 3 0.915 0.922 0.912 0.860 0.879 0.892 0.070 0.064 0.061 0.145 0.123 0.119
Table 6: Simulated coverage probabilities and Type I error rates for different configurations
of ∆, σ2, α, and nℓ under Scenario 4.
significance level α for all configurations investigated here, indicating that the hypothesis
test (14) is indeed a level-α test, even under total sample sizes as small as 30.
The right side of Table 6 displays the simulated Type I error rates under Scenario 4. As
before, the simulated Type I error rate is bounded by the nominal significance level α under
almost all configurations. The test can be liberal for small sample sizes and large values of
∆, matching the observed performance of the confidence bounds shown in the left side of
Table 6. Again, this size inflation disappears for large sample sizes.
3.3.3 Power
For the power simulations we again considered the two scenarios from Figure 7 and start
with Scenario 3. Because |MED1 −MED2| = 0 for all values of ∆, the power of the test
depends only on the given threshold η. For the concrete simulations, we set ∆ = 1 and used
δ1 = 1 for convenience. For each configuration of σ
2 = 1, 2, 3 and η = 0.1, 0.2, 0.5, 1, we used
(7) to simulate n = 10(30, 50) observations under m1 and m2 at each dose level dℓ,i, resulting
in nℓ = 30(90, 150), ℓ = 1, 2. All configurations belong to the alternative in (13). Table 7
summarizes the results for α = 0.05, 0.1. The power increases with increasing values of η.
The power decreases for larger values of σ2, especially for small values of η. In these cases
we need larger sample sizes nℓ in order to achieve reliable results.
For the final set of simulations, we revisit Scenario 4 and investigate the power for different
values of σ2 and ∆. We set η = 0.8 and nℓ = 30, 150 for ℓ = 1, 2 and summarize the results
in Table 8. In alignment with all former results, the performance of the test is worse in case
of ∆ = 2.4 due to the already mentioned numerical problems when calculating the MEDs.
In general, the power increases with increasing sample sizes and decreasing variances under
all observed configurations. The power converges to 1 for n1, n2 →∞.
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α = 0.05 α = 0.1
η σ2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
1 1 0.979 1.000 1.000 0.989 1.000 1.000
0.5 1 0.679 0.988 0.999 0.783 0.995 1.000
0.2 1 0.116 0.364 0.641 0.226 0.543 0.784
0.1 1 0.061 0.086 0.123 0.123 0.179 0.232
1 2 0.823 0.997 1.000 0.893 0.999 1.000
0.5 2 0.400 0.853 0.975 0.524 0.915 0.987
0.2 2 0.078 0.167 0.283 0.163 0.288 0.462
0.1 2 0.055 0.066 0.077 0.109 0.132 0.156
1 3 0.703 0.985 1.000 0.794 0.989 1.000
0.5 3 0.265 0.691 0.897 0.401 0.788 0.936
0.2 3 0.075 0.112 0.168 0.145 0.214 0.311
0.1 3 0.047 0.050 0.068 0.116 0.132 0.130
Table 7: Simulated power for different configurations of η, σ2, α, and nℓ in Scenario 3.
α = 0.05 α = 0.1
∆ σ2 nℓ = 30 nℓ = 90 nℓ = 150 nℓ = 30 nℓ = 90 nℓ = 150
0.4 1 0.914 1.000 1.000 0.958 1.000 1.000
0.8 1 0.116 0.404 0.625 0.261 0.609 0.778
1.6 1 0.057 0.080 0.080 0.118 0.129 0.152
2.4 1 0.090 0.093 0.118 0.163 0.149 0.233
0.4 2 0.668 0.984 0.999 0.806 0.990 0.999
0.8 2 0.089 0.168 0.324 0.183 0.350 0.523
1.6 2 0.058 0.073 0.060 0.116 0.099 0.122
2.4 2 0.081 0.093 0.093 0.165 0.127 0.189
0.4 3 0.545 0.921 0.992 0.681 0.954 0.993
0.8 3 0.075 0.110 0.203 0.177 0.259 0.398
1.6 3 0.076 0.064 0.065 0.102 0.102 0.120
2.4 3 0.070 0.069 0.086 0.146 0.121 0.185
Table 8: Simulated power for different configurations of ∆, σ2, α, and nℓ in Scenario 4.
4 Conclusions
In this paper, we used the results from [10] to derive a confidence interval for the maximum
difference between two given non-linear regression models over the entire covariate space of
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interest and considered asymptotic methods to derive confidence intervals for the difference
between two same target doses. One reviewer suggested comparing location and shape of the
dose response curves as a third way of assessing similarity in dose finding trials, in addition
to the proposed assessments of similarity in dose response and target doses. One limitation
of such an approach could be that even if two dose response functions have exactly the same
location and shape, their curves could be very different. Consider, for example, the two
Emax curves given by m1(d) = 1 + 6d/(0.2 + d) and m2(d) = 1 + 6d/(3 + d). Plotting
those two curves, one recognizes immediately that they are very different although location
and shape are the same. Building upon this comment, however, one possibility would be to
construct a multivariate equivalence test on the entire model parameter vector. One could
consider testing, for example, the null hypothesis H˜ : ‖ϑ1 − ϑ2‖22 ≥ δ against the alternative
hypothesis K˜ : ‖ϑ1 − ϑ2‖
2
2 < δ for small values of δ. Such a multivariate equivalence test
could only be constructed if the two regression models are the same, which is a limitation
compared to the methods proposed in this paper. In addition, non-parametric approaches
could be considered such as the empirical probability plots presented by [17, 18]. Such
approaches, however, may not readily apply to the situations considered in this paper and
one would have to extend the theory considerably.
The choice of the equivalence margins δ and η in (4) and (13), respectively, is a delicate
problem. This choice depends on the particular application and has to be made by clinical
experts, possibly with input from statisticians and other quantitative scientists. Regulatory
guidance documents are available in specific settings, such as for the problem of demon-
strating bioequivalence. For example, [19] discusses how the thresholds for bioequivalence
hypotheses of the form considered in this paper can be defined in various settings. For
the comparison of curves as considered in this paper we refer to Appendix 1 of [19], with
emphasis on dissolution profiles on the basis of specific measures.
A practical concern for any clinical trial is to determine its appropriate sample size. Related
calculations at the trial design stage of a regular Phase II dose finding trial could be based ei-
ther on power considerations to achieve a pre-specified probability of establishing a true dose
response signal or on a pre-specified precision for dose response and target dose estimation.
Using the methods proposed in this paper, sample size calculations will be based on testing
the hypotheses H,H ′, and H ′′ in the previous sections, such that the desired probability of
rejecting the true null hypothesis under an assumed dose response curve is achieved. One
may therefore justify the sample size using power calculations, with simulations performed
to ensure adequate performance (as illustrated in Sections 2.3.3 and 3.3.3). In practice, the
requirements for demonstrating similarity of target doses or dose response curves are more
relaxed, not least because we may not have enough patients in the individual subgroups.
A particular application area of the proposed methods are multiregional clinical trials, which
are run in different countries or regions, and potentially serve different submissions [20]. For
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example, many pharmaceutical companies focus on running multiregional clinical trials that
include a major Japanese subpopulation for later regulatory submission in Japan. A natural
question is then whether the dose response results for the Japanese and the non-Japanese
populations are consistent [25, 26]. For this purpose, the ICH E5 guideline [21] recommends
a separate trial to compare the dose response relationships between the two regions. This
document triggered considerably research (see [22, 23, 24] among many others), although
most literature at that time focused on bridging trials which is different to the situation
considered here. Acknowledging that the comparison between two regions is not just a
subgroup analysis problem [20], it would be interesting to see to which extent the proposed
methods remain applicable in multiregional clinical trials.
In this paper, we focused on the comparison of two, possibly different, dose response models
m1 and m2. In many situations limited information about the shape of the dose response
curve is available at the trial design stage. For example, information might be available
about the dose response curve for a similar compound in the same indication or the same
compound in a different indication. Also, dose exposure response models might have been
developed based on earlier data (e.g. from a proof-of-concept trial). Such information can be
used for the clinical team to agree on a candidate dose response model. While empirical ev-
idence suggests that the Emax model is often observed in clinical dose finding trials [27, 28],
model uncertainty remains of practical concern and is often underestimated. Especially, in
the context of subgroup analysis and multiregional clinical trials the dose response models
could be very different between subgroups and regions, respectively. Selecting a single model
discards model uncertainty, which may lead to confidence intervals with a coverage proba-
bility smaller than the nominal level. Thus, alternative model selection and model averaging
approaches have been investigated in the context of dose finding in Phase II [29], including
the MCP-Mod approach [30, 31, 32]. We leave the extension of the methods proposed in
this paper to situations facing model uncertainty for future research.
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A. Coverage probability of the confidence interval for
the maximum absolute difference
In the following we prove equation (2) from Section 2.1. To this end, let d0 ∈ D such that
max
d∈D
|m2(ϑ2, d)−m1(ϑ1, d)| = |m2(ϑ2, d0)−m1(ϑ1, d0)|.
Hence
P = P
{
max
d∈D
|m2(ϑ2, d)−m1(ϑ1, d)| ≤ max
{
max
d∈D
U (Y1, Y2, d) ,−min
d∈D
L (Y1, Y2, d)
}}
= P
{
|m2(ϑ2, d0)−m1(ϑ1, d0)| ≤ max
{
max
d∈D
U (Y1, Y2, d) ,−min
d∈D
L (Y1, Y2, d)
}}
≥ P
{
|m2(ϑ2, d0)−m1(ϑ1, d0)| ≤ max
{
U (Y1, Y2, d0) ,−L (Y1, Y2, d0)
}}
.
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Now we distinguish two cases. If m2(ϑ2, d0)−m1(ϑ1, d0) ≥ 0 we have
P ≥ P
{
m2(ϑ2, d0)−m1(ϑ1, d0) ≤ U (Y1, Y2, d0)
}
n1,n2→∞−→ 1− α, (16)
as U (Y1, Y2, d) is a 1− α pointwise upper confidence bound on m2(ϑ2, d)−m1(ϑ1, d). Oth-
erwise, m2(ϑ2, d0)−m1(ϑ1, d0) ≤ 0 and the same argument applies to L (Y1, Y2, d), yielding
P ≥ P
{
m2(ϑ2, d0)−m1(ϑ1, d0) ≥ L (Y1, Y2, d0)
}
n1,n2→∞−→ 1− α. (17)
B. Asymptotic level of the test for similarity of two tar-
get doses
We show that the test (14) defined in Section 3.1 has asymptotic level α, that is
lim
n1,n2→∞
P
(
|M̂ED1 − M̂ED2| ≤ c
)
≤ α (18)
under the null hypothesis. First note that the solution of equation (15) is unique as the
function c→ Φ
(
c−η
τˆ
)
−Φ
(
−c−η
τˆ
)
is strictly increasing with limits −1 and 1 as c→ −∞ and
∞, respectively. Next, let t = MED1−MED2, tˆ = M̂ED1− M̂ED2 and denote the power
function of the test by
Gn1,n2(θ) = P
(∣∣tˆ∣∣ < c) .
The assertion (18) is then equivalent to
lim
n1,n2→∞
Gn1,n2(θ) ≤ α for all |t| ≥ η. (19)
A standard calculation shows that
Gn1,n2(t) = P (|tˆ| ≤ c) = P (−c ≤ tˆ ≤ c) = P
(−c− t
τˆ
≤
tˆ− t
τˆ
≤
c− t
τˆ
)
n1,n2→∞
−→ G˜(t) := Φ
(c− t
τ
)
− Φ
(−c− t
τ
)
Now consider the problem of testing the hypotheses H : |t| ≥ η against K : |t| < η for
normally distributed data X ∼ N (t, τ 2). A simple calculation shows that the (asymptotic)
power function G˜ coincides with the power of the test, which rejects the null hypothesis
H : |t| ≥ η whenever |X| ≤ c. Considering the discussion in Lehmann et al. [33, p. 81],
it follows that this test is uniformly most powerful and unbiased of size α. This implies
G˜(t) ≤ G˜(η) = α for all |t| ≥ η and proves (19).
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